Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MARION MERRELL DOW’s SELDANE OTC IS "ON HOLD"

Executive Summary

MARION MERRELL DOW's SELDANE OTC IS "ON HOLD" as MMD and FDA work on "the mechanism" for designing a study to address concerns about cardiovascular side effects associated with the nonsedating antihistamine terfendine. MMD President Fred Lyons told Mabon Nugent's fifth annual research conference Dec. 5: "We, with FDA, have agreed to put on hold [OTC Seldane] until we identify the issues" and extent of possible episodes of torsades de pointes prolonged QT intervals and/or ventricular arrhythmias associated with the product. Lyons noted the difficulty of creating a protocol to investigate the cardiovascular side effects. For example, a "2,500 patient study" is inadequate to assess cardiovascular events from Seldane OTC when the incidence of torsades de pointes reported for the prescription version has been about "one in four million cases," he stated. MMD believes the answer "may be through an epidemiology approach," Lyons added, noting that MMD is "working now with FDA on the mechanism." Following FDA's Pulmonary-Allergy Drugs Advisory Committee's review of prescription Seldane and the issue of torsade de pointes ("The Pink Sheet" June 18, p. 6), Marion Merrell Dow has relabeled Seldane. The revised labeling includes a discussion of overdose and cautions against terfenadine's use by people with impaired liver function. The company believes that Seldane patients who also were taking ketoconazole or had cirrhosis of the liver metabolized Seldane differently, thus resulting in some incidents of overdose. The company also issued a "Dear Doctor" letter on possible Seldane cardiovascular side effects. While the committee did not formally recommend a "Dear Doctor" letter, three members strongly suggested that one be sent to advise physicians of the labeling changes. The adverse publicity from the June advisory committee meeting and the subsequent "Dear Doctor" letter resulted in a "short-term" decline in Seldane prescriptions, Lyons acknowledged. However, September-October script data shows that Seldane numbers are "exceeding pre-June growth rates," he noted. The spillover from Seldane's appearance before the agency committee does not appear to have affected MMD's expectations for the approval of the Seldane-D antihistamine-decongestant prescription product. "We hope for approval in the not too distant future," Lyons said. There "are no pending issues on that."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel